The First Smartphone-Controlled, Prescription Wearable Device for the Acute Treatment of Migraine, Nerivio, Wins Silver at MDEA
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-approved acute migraine treatment wearable Nerivio® has been named a silver winner of the 2021 Medical Design Excellence Awards (MDEA) in the Digital Health Products and Mobile Medical Apps category.
The MDEA, organized by Informa Markets – Engineering, is an award program dedicated to recognizing cutting-edge achievements in medical product design and celebrating the industry’s foremost manufacturers designing groundbreaking medical devices that are changing patient care worldwide.
“We are honored to be recognized by the Medical Design Excellence Awards for the advanced technology behind Nerivio. The unique design and usability of the device makes it an effective treatment option and we are committed to continuing to provide patients with accessible pain relief,” said Ronen Jashek, COO and co-founder of Theranica. “Nerivio is advancing the migraine treatment market by expanding the options beyond medication – a long awaited shift in the field. Thank you to the jurors for recognizing this important alternative first-line treatment that helps patients manage this debilitating and pervasive condition.”
Theranica’s FDA-cleared prescr
Nerivio was also named as one of TIME’s best inventions of 2019. Patients interested in Nerivio should visit the device’s website. Eligible for insurance coverage, Nerivio is available by prescription by any licensed healthcare provider, and via telemedicine platform UpScript. Nerivio is delivered directly to the patient’s home. Every Nerivio unit is good for 12 treatments, after which it can be recycled, and the prescription refilled with a new device.